Acronyms are used to give studies a short memorizable name. These studies
appear more often in citations (http://www.rheumatologyupdate.com.au/news/acronyms-increase-impact-of-clinical-trials).
Nobody can remember all these studies. So I've selected the more important
ones. I limited this overview to studies on rheumatoid arthritis, psoriatic
arthritis, and ankylosing spondylitis. The studies had to appear in discussions
at different ACR and EULAR Meetings, journals. And I've also added some
pseudo-acronyms, acronyms of registries, and some acronyms of associations,
which are used in the discussions. If I have omitted a relevant study, please
let me know. This is an ongoing project.
This is my second approach; therefore I call it “Acronyms of Studies in
Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis 2.0”. I
started the version 1.0 in 2012 and updated it until the End of 2016. It
contains lots of new, but all of the old entries.
ABILITY-1 efficacy and safety of adalimumab in patients with
non-radiographic axial spondyloarthritis
A-BREAK bridging vacation in patients on s.c. abatacept with i.v.
abatacept and back to s.c. abatacept
ABILITY-2 adalimumab in patients with peripheral spondyloarthritis
ACCELERATE RA study??? I’ve found: evacetrapib in participants with high-risk vascular
disease (a study in cardiology)
ACCOMPANY subcutaneous abatacept in RA with and without methotrexate
ACHILLES ??? a study in angiology?
ACQUIRE subcutaneous abatacept versus intravenous abatacept
ACTION a randomized placebo-controlled, blinded study of escalating doses
of ocrelizumab
ACTION real-world effectiveness of abatacept for rheumatoid arthritis
ACT-LIFE usage and dosification patterns of tocilizumab in the treatment
of rheumatoid arthritis (RA)
ACT-RAY actemra (tocilizumab) radiographic study
ACT-SURE actemra (tocilizumab) [unclear what sure stands for]
ADACTA adalimumab actemra (tocilizumab) head-to-head-study
ADAMO study to compare the efficacy and safety of denosumab vs. placebo
in males with osteoporosis
ADEPT the adalimumab effectiveness in psoriatic arthritis trial
ADJUST abatacept study to determine the effectiveness in preventing the
development of rheumatic arthritis in patients with undifferentiated
inflammatory arthritis and to evaluate safety and tolerability
ADMIRE adalimumab in rheumatoid arthritis patients in stable clinical
remission
AGREE abatacept study to gauge remission and joint damage in early
erosive rheumatoid Arthritis
AIM abatacept in inadequate responders to methotrexate
ALLOW subcutaneous abatacept in RA - impact of withdrawal and
reintroduction
AMARA rituximab in combination with leflunomide in rheumatoid arthritis
AMBITION actemra versus methotrexate double blind investigative trial in
monotherapy
AMPLE abatacept vs. adalimumab in biologic naive RA patients with
background MTX
APPEAL randomized comparison of etanercept with usual therapy in an Asian
population
APPRAISE prospective, multinational study using the composite
greyscale/PDUS synovitis score
ARCTIC ultrasound in rheumatoid arthritis patients under a T2T therapy
ARMADA anti-TNF factor research study program of the monoclonal antibody
adalimumab (D2E7) in rheumatoid arthritis
ARRIVE abatacept researched in RA patients with inadequate anti-TNF
response to validate effectiveness
ARTIS Swedish biologics register
ASAS/COMOSPA - evaluation of co-morbidities in spondyloarthritis
AS - EARLY etanercept in early non-radiographic axial spondyloarthritis
ASPIRE active controlled study of patients receiving infliximab for the
treatment of rheumatoid arthritis of early onset
ASSERT ankylosing spondylitis study for the evaluation of recombinant
infliximab therapy
ASTRAEA active psoriatic arthritis randomized trial
ATACC-RA a transatlantic cardiovascular risk calculator for rheumatoid
arthritis
ATLAS adalimumab trial evaluating long term efficacy and safety for
ankylosing spondylitis
ATTAIN abatacept trial in treatment of anti-TNF inadequate
ATTEST a trial for tolerability, efficacy, and safety in treating
rheumatoid arthritis (infliximab)
ATTRA Czech national registry
ATTRACT anti-TNF trial in rheumatoid arthritis with concomitant therapy
ATTUNE switch from intravenous to subcutaneous abatacept
AVERT a very early rehabilitation trial (abatacept) / another source has:
a very early rheumatoid arthritis treatment
AWAKEN abatacept withdrawal study to assess efficacy and safety in key
endpoints in juvenile idiopathic arthritis not responding to current treatment
BALANCE I ABT-494, a JAK-a-inhibitor in rheumatoid arthritis patients
BARFOT better antirheumatic farmacotherapy (prednisolone)
BeST behandelings strategie
BiKeR German biologics registry for juveniles
BiOCURA biologicals and outcome compared and predicted Utrecht region in
Rheumatoid Arthritis cohort
BIOSPAR Leuven spondyloarthritis biologics cohort
BioTRAC Canadian register
BREVACTA tocilizumab by subcutaneous injection in patients with
rheumatoid arthritis
BRIGHT adalimumab - correct name?
BRILL British rheumatoid interstitial lung cohort
BSRBR-RA British Society for Rheumatology biologic register for
rheumatoid arthritis
C-EARLY certolizumab in early, active rheumatoid arthritis
CAMEO etanercept compared to etanercept plus methotrexate in moderate to
severe rheumatoid arthritis
CAMERA 2 computer assisted management in early rheumatoid arthritis
CAPEA Course and Prognosis of Early Arthritis
CAPRA circadian administration of prednisone in rheumatoid arthritis
(modified release prednisone)
CareRA MTX monotherapy against MTX combination with another synthetic
DMARD in DMARD naive RA patients with unfavorable prognosis
CASSANDRA cervical arthritis screening and treatment in RA
CATCH Canadian early arthritis cohort
C-EARLY efficacy and safety of certolizumab pegol in combination with
methotrexate in the treatment of DMARD-naïve adults with early active
rheumatoid arthritis
CERTAIN efficacy and safety of certolizumab pegol after incomplete
response to DMARDS in RA patients with low to moderate disease activity
CHERISH tocilizumab in polyarticular juvenile idiopathic arthritis
CIMAX certolizumab in axial spondyloarthritis (noninterventional study)
CIMESTRA ciclosporin, methotrexate, steroid in rheumatoid arthritis
CLEAR efficacy of secukinumab compared to ustekinumab in patients with
plaque-type psoriasis
COBRA combinatie therapie bij reumatoide artritis
COMEDRA comorbidities in rheumatoid arthritis
COMET combination of methotrexate under etanercept in early rheumatoid
arthritis
COMORA prevalence of comorbidities in rheumatoid arthritis
COMOSPA - evaluation of co-morbidities in spondyloarthritis
CONCERTO combination therapy with adalimumab in subjects with early
rheumatoid arthritis
CONIFER
CORRONA consortium of rheumatology researchers of north america database
DANBIO database for Danish patients on biologics
DANCER dose ranging assessment – international clinical evaluation of
rituximab in rheumatoid arthritis
DARWIN drug against rheumatoid arthritis with selective JAK1 inhibition
(filgotinib)
Discover-1 efficacy and safety of guselkumab s.c. in participants with
active psoriatic arthritis including those previously treated with biologic
anti -tumor necrosis factor (TNF) alpha agent(s)
DOSERA effect on disease activity when reducing or discontinuing
etanercept in subjects with RA
DREAM Dutch rheumatoid arthritis monitoring
DRESS spacing injection intervals or pause adalimumab or etanercept in RA
patients
EAC early arthritis clinic (Leiden)
EARC early arthritis recognition clinics (Leiden) [not the same as EAC!]
EARTH consistent efficacy and safety outcomes between European and Japanese
subjects with rheumatoid arthritis following treatment with mavrilimumab
EARTH EXPLORER-1 mavrilimumab in subjects with rheumatoid arthritis and
inadequate response to methotrexate
EASIC ankylosing spondylitis infliximab cohort
EIRA epidemiologic investigation of rheumatoid arthritis (Sweden)
EMBARK clinical and MRI responses to etanercept in non-radiographic axial
spondyloarthritis
ENRADAS effects of NSAIDs on radiographic damage in ankylosing
spondylitis
ENTRACTE tocilizumab in comparison to etanercept in participants with
rheumatoid arthritis and cardiovascular disease risk factors
era early rheumatoid arthritis
ERASURE efficacy of response and safety of two fixed secukinumab regimens
in psoriasis
ESPERA experimental study of periodontitis and rheumatoid arthritis
ESPOIR a large national multicenter, longitudinal and prospective cohort
initiated by the French Society of Rheumatology
ESTHER effects of etanercept versus sulfasalazine in early axial spondyloarthritis
on active inflammatory lesions as detected by whole-body magnetic resonance
imaging
FasT not interventional study concerning certolizumab
FAST4WARD efficacy and safety of certolizumab pegol – 4-weekly dosage in
rheumatoid arthritis
FILM safety and efficacy of ocrelizumab in combination with methotrexate
FINRACO Finnish rheumatoid arthritis combination therapy
FIRST rituximab after first TNF-inhibitor
FIXTURE full year investigative examination of secukinumab vs. etanercept
Using two dosing regimens to determine efficacy in psoriasis
FORCAST follow up research cohort in ankylosing spondylitis
FREEDOM discontinuation of denosumab and associated fracture incidence
FUNCTION efficacy and safety of tocilizumab with or without methotrexate
in patients with early rheumatoid arthritis, who are methotrexate naive
FUTURE 1/2 secukinumab in psoriatic arthritis
GEMS Guildford evaluation of methotrexate
GERINIS rituximab in patients with rheumatoid arthritis in routine
practice
GESPIC German spondyloarthritis inception cohort
GiACTA giant-cell arteritis actemra trial
GISEA gruppo taliano studio early arthritis
GO-AFTER golimumab after anti-TNF in rheumatoid arthritis patients
GO-AHEAD golimumab in active nr-axSpA
GO-BEFORE golimumab in active rheumatoid arthritis before methotrexate
therapy
GO-FORWARD golimumab in active rheumatoid arthritis despite methotrexate
therapy
GO-FURTHER intravenous golimumab for active rheumatoid arthritis
GO-KIDS golimumab in children with juvenile idiopathic arthritis (JIA)
and multiple joint involvement and poor response to methotrexate
GO-MONO golimumab monotherapy in patients with active rheumatoid
arthritis
GO-MORE subcutaneous golimumab for rheumatoid arthritis, followed by
intravenous/subcutaneous golimumab strategy
GO-NICE non interventional study of golimumab in RA patients
GO-RAISE golimumab in active ankylosing spondylitis (did you see the R?
actually all GO-plus study names aren´t clean acronyms)
GO-REVEAL golimumab in active psoriatic arthritis
GO-VIBRANT a study of golimumab in participants with active psoriatic
arthritis
GRACE GRAPPA composite exercise
GRAPPA group for research and assessment of psoriasis and psoriatic
arthritis
GRAND 1-3 studies on denosumab in osteoporosis
GUEPARD guérir la polyarthrite rheumotoide débutante (adalimumab)
GUESS Glasgow ultrasound enthesitis screening system
HIT HARD high induction therapy with anti-rheumatic drugs (adalimumab and
methotrexate)
HONOR humira discontinuation without functional and radiographic damage
progression following sustained remission
HOPEFUL Japanese study on adalimumab in combination with low-dose MTX
ICHIBAN non interventional study on safety and efficacy of tocilizumab in
RA patients
Illuminate-1 tabalumab vs. placebo in SLE
Illuminate-2 tabalumab vs. placebo in SLE
Illuminate-X tabalumab vs. placebo in SLE open label
IMPACT infliximab multinational psoriatic arthritis controlled trial
IMPROVED remission induction therapy with methotrexate and prednisone in
patients with early rheumatoid and undifferentiated arthritis
INFAST infliximab for treatment of axial spondyloarthritis
INFAST 2 infliximab for treatment of axial spondyloarthritis, maintenance
of biologic free remission
JuMBO juvenile arthritis methotrexate/biologics long-term observation
registry as follow-up-registry of BiKeR
LATIN-RA ??? someone recently
cited such a study, which I've never had heard about before
LAUNCH long term safety and efficacy of multiple rituximab cycles in RA
LITHE tocilizumab safety and the prevention of structural joint damage)
methotrexate and sulfasalazine combination trial
LOPAS longterm outcome in psoriatic arthritis
MACE major adverse cardiovascular events
MAPP multinational assessment of psoriasis and psoriatic arthritis
MASTER multicenter ankylosing spondylitis survey trial to evaluate and
compare referral parameters in early SpA
MEASURE 1/2 secukinumab in ankylosing spondylitis
MIPA methotrexate in psoriatic arthritis
MIRAI early response to tocilizumab (actually it isn't an acronym; mirai
is Japanese [未来 / みらい] for future - so let's
call it a pseudo-acronym)
MOSAICS managing osteoarthritis in consultations
MUSICA methotrexate dose in RA patients under adalimumab
NEXUS namilumab phase IIb in rheumatoid arthritis (anti-GM-CSF-MAB)
NOAR Norfolk arthritis register
NOR-DMARD a Norwegian 5-center register
NOR-SWITCH non inferiority study of infliximab biosimilar CT-P13 vs.
infliximab originator
OASIS outcome assessment in ankylosing spondylitis international study
(etanercept)
OPAL broaden oral psoriatic arthritis trial (tofacitinib)
OPAL beyond oral psoriatic arthritis trial (tofacitinib) in patients with
inadequate response to TNFi
OPERA optimized treatment algorithm for patients with early rheumatoid
arthritis
OPPOSITE infliximab in active rheumatoid arthritis after DMARD therapy
OPTIMA optimal protocol for treatment initiation with methotrexate and
adalimumab
OPTIMIZE ???
OPTION tocilizumab pivotal trial in methotrexate inadequate responders
OPTTIRA optimizing treatment with tumor necrosis factor inhibitors in
rheumatoid arthritis (dose tapering) ORAL Scan / 24-month study in inadequate
responders to MTX receiving tofacitinib and background MTX
OPAL BEYOND tofacitinib in psoriatic arthritis subjects with inadequate
response to TNF inhibitors
ORAL Sequel / Phase 2/3 open label follow-up study evaluating patients
who had participated in a prior randomized Phase 2 or Phase 3 study of
tofacitinib (monotherapy or in combination with traditional DMARDs)
ORAL Solo / 6-month monotherapy study in inadequate responders to a DMARD
(traditional or biologic) receiving tofacitinib monotherapy
ORAL Standard / 12-month study in inadequate responders to MTX receiving
tofacitinib and background MTX, with active control of adalimumab and
background MTX
ORAL Start / 24-month study in MTX-naïve patients receiving tofacitinib
monotherapy or MTX
ORAL Step / 6-month study in inadequate responders to TNF-inhibiting
therapy receiving tofacitinib and background MTX
ORAL Sync / 12-month study in inadequate responders to a DMARD
(traditional or biologic) receiving tofacitinib and background traditional
DMARD(s)
ORBIT orencia as biological infusion treatment for RA
ORION orencia remission induction and outcome navigation
OSKIRA oral SYK inhibition in rheumatoid arthritis - fostamatinib
PALACE apremilast in active psoriatic arthritis
PARA pregnancy induced amelioration of rheumatoid arthritis
PASE psoriatic arthritis screening and evaluation
PHOENIX 1 and 2 long-term efficacy of ustekinumab in patients with
moderate-to-severe psoriasis (not arthritis, but are cited for reasons of drug
safety)
PEST psoriasis epidemiology screening tool
POEET potential optimalisation of expediency of TNFi study
POET-US part of POEET, if ultrasound may predict flares
PLANETAS comparison between infliximab an CT-P13 in ankylosing
spondylitis
PLANETRA CT-P13 (infliximab biosimilar) with methotrexate in patients
with active rheumatoid arthritis
PRAIRI prevention of rheumatoid arthritis by rituximab
PREDICT ? infliximab in patient with psoriatic arthritis?
PREMIER patients receiving methotrexate and infliximab for the treatment
of early rheumatoid arthritis
PREMIER LTE patients receiving methotrexate and infliximab for the
treatment of early rheumatoid arthritis, long term extension
PRESERVE etanercept in rheumatoid arthritis, dose reduction after one
year
PRESTA psoriasis randomized etanercept study in subjects with psoriatic
arthritis
PRINTO paediatric rheumatology international trials organisation (?)PRIZE
producticity an remisssion in a randomized controlled trial of etanercept vs.
standard care in early rheumatoid arthritis
PRIORA namilumab in patients with mild to moderate rheumatoid arthritis
(anti-GM-CSF-MAB)
PRIZE assessing maintenance of remission after withdrawal of etanercept
plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis
patients who achieved remission with etanercept and methotrexate: the PRIZE
study
PROMPT probable rheumatoid arthritis – methotrexate versus placebo
treatment
PSUMMIT ustekinumab in patients with psoriatic arthritis
RA-BEACON a moderate to severe rheumatoid arthritis study (baricitinib)
RA-BEAM baricitinib vs. placebo and vs. adalimumab
RA-BEGIN baricitinib vs. methotrexate
RA-BUILD a moderate to severe rheumatoid arthritis study participants
(baricitinib)
RA-Score MRI study in RA patients treated with rituximab
RABBIT German register for patients on biologics
RACAT rheumatoid arthritis comparison of active therapies
RADIATE research on actemra determing efficacy after anti-TNF failure
RAISE - rheumatoid arthritis independent Swiss treatment expectations and
outcome (abatacept)
RAMS rheumatoid arthritis methotrexate study
RAPID rheumatoid arthritis prevention of structural damage
RAPID-axSpA certolizumab in axial spondyloarthritis
RAPID-PsA certolizumab in psoriatic arthritis
RATE-RA shortening infusion time in rituximab
REACH Rotterdam early arthritis cohort
REACT research in active rheumatoid arthritis
Re-FIRST rituximab follow-up study to the FIRST study
REALISTIC RA evaluation in subjects receiving tnf inhibitor certolizumab
pegol
REFLEX randomized evaluation of long-term efficacy of rituximab
REMARCA Russian investigation of methotrexate and biologics in early
active inflammatory arthritis
REMARK ifliximab in active rheumatoid arthritis
RESTART active rheumatoid arthritis with insufficient response to
etanercept or adalimumab and methotrexate
RETREAT (F) feasibility of methotrexate withdrawal
RETRO a non-interventional study in RA patients to look at dose reduction
of conventional and biologic DMARDs
RHAPSODY review of safety and effectiveness with adalimumab in Patients
with active ankylosing spondylitis
RISA-III rheumatology integration into student education
RISING dose escalation of infliximab in MTX refractory RA patients
RISING impact on radiographic and clinical response to infliximab therapy
ROAD research on osteoarthritis against disability
ROC rotation or change of biotherapy after first anti-TNF treatment
failure for rheumatoid arthritis, a French study
ROSE tocilizumab in rheumatoid arthritis patients with previous
inadequate response to DMARDs
RRR a Japanese study on remicade remission in rheumatoid arthritis
patients
SAMURAI study of active controlled monotherapy used for rheumatoid
arthritis, an IL-6 inhibitor
SARIL-RA-ASCERTAIN safety and tolerability of sarilumab and tocilizumab
in patients with rheumatoid arthritis
SARIL-RA-EASY auto-injector device in patients with rheumatoid arthritis
SARIL-RA-MOBILITY sarilumab on top of methotrexate in rheumatoid
arthritis patients
SARIL-RA-MONARCH efficacy and safety of sarilumab and adalimumab
monotherapy in patients with rheumatoid arthritis
SARIL-RA-TARGET efficacy and safety of sarilumab added to non-biologic DMARD
therapy in patients with rheumatoid arthritis SATORI study of active controlled
tocilizumab for rheumatoid arthritis patients with an inadequate response to
methotrexate
SCRIPT study to evaluate the safety and efficacy of ocrelizumab compared
to placebo in patients with active rheumatoid arthritis who have had an
inadequate response to at least one anti-TNF thearpy
SIRROUND-D sirukumab in patients with active rheumatoid arthritis despite
DMARD therapy
SIRROUND-H comparison of sirukumab to adalimumab monotherapy in patients
with active rheumatoid arthritis
SIRROUND-LTE long term extension to evaluate sirukumab in patients with
active rheumatoid arthritis
SIRROUND-T sirukumab in patients with active rheumatoid arthritis despite
TNFi therapy
SMILE safety of methotrexate in combo with leflunomide in rheumatoid
arthritis
SPACE spondyloarthritis caught early cohort
SPAH Sao Paulo aging and health study
SPARSE spondyloarthritis responds to etanercept
SPIRIT-P1 ixekizumab vs. placebo vs. adalimumab in rheumatoid arthritis
STAGE Study to evaluate the safety of ocrelizumab compared to placebo in
patients with active rheumatoid arthritis continuing methotrexate treatment
STAR safety trial of adalimumab in rheumatoid arthritis
START safety trial for rheumatoid arthritis with remicade therapy
STEREO safety and efficacy of adalimumab in patients with active
psoriatic arthritis - an open-label, multinational study to evaluate the
response to every-other-week adalimumab when added to insufficient standard
therapy including patients who failed prior treatment with other tnf-inhibitors
STRASS spacing of TNF-blocker injections in rheumatoid arthritis study
STREAM long-term safety and efficacy of tocilizumab
SUMMACTA subcutaneous formulation of tocilizumab in patients with
rheumatoid arthritis
SUNRISE retreatment with rituximab in patients with rheumatoid arthritis
receiving background methotrexate
SWEFOT Swedish pharmacotherapy
SWITCH-RA rituximab versus an alternative TNF inhibitor in patients with
rheumatoid arthritis who failed to respond to a single previous TNF inhibitor
TAMARA tocilizumab and DMARDs achievements in rheumatoid arthritis
TaSER treat to target in patients with early rheumatoid arthritis with
the help of ultrasound
TEAR treatment of early aggressive rheumatoid arthritis
TELLUS namilumab vs adalimumab in participants with moderate to severe
early arthritis inadequately responding to methotrexate
TEMPO trial of etanercept an methotrexate with radiographic outcomes
TICOPA comparing tight control of early psoriatic arthritis
TICORA tight control for rheumatoid arthritis
TIRA early interventions in rheumatoid arthritis - Swedish cohort
TOCERRA tocilizumab collaboration of European registries in rheumatoid
arthritis
TOMORROW total mangement of risk factors in RA patients to lower
morbidity and mortality
TOPAS ustekinumab for the treatment of patients with active ankylosing
spondylitis
TOPAS Toronto psoriatic arthritis screening
TORPEDO study on rapid effect of
tocilizumab in patients with rheumatoid arthritis
TOWARD tocilizumab in combination with traditional DMARD therapy)
TRACE-RA statin therapy may prevent CVD in rheumatoid arthritis
tREACH trial in patients with recent-onset of arthritis
TREAT-JIA trial of early aggressive drug therapy in juvenile idiopathic
arthritis (etanercept and MTX)
TRUST a tocilizumab study from Italy
TryCort diagnostic value of oral prednisolone test for rheumatoid
arthritis
TSORA trichiuris suis ova in patients with rheumatoid arthritis and
inadequate response to methotrexate
U-ACT-EARLY tocilizumab and methotrexate in combination or as Monotherapy
in treatment-naïve patients eith early rheumatoid arthritis 3P Survey
assessment of behaviour of French rheumatologists to the prescription of
synthetic and biologic DMARDs
UNCOVER-1 ixekizumab vs. placebo in patients with psoriasis
UNCOVER-2 ixekizumab vs. etanercept and vs. placebo in patients with
psoriasis
UNCOVER-3 ixekizumab vs. etanercept and vs. placebo in patients with
psoriasis
VISUAL I+II adalimumab in pats. with noninfectious anterior Uveitis
And a list for three letter abbreviations of DMARDs:
ABA - abatacept
ADA - adalimumab
APR - apremilast
AZA – azathioprine
BAR – baricitinib
CLQ – chloroquine (also CQ)
CyA - cyclosporine A
CZP - certolizumab
ETN - etanercept
GLM – golimumab
HCQ - hydroxychloroquine
IFX - infliximab
LEF - leflunomide
MMF - mycophenolate
MTX – methotrexate
RTX - rituximab
SSZ - sulfasalazine
SEC - secukinumab
TFB - tofacitinib
TOC – tocilizumab
UST - ustekinumab
The following abbreviations are common now:
csDMARD - conventional (like MTX or leflunomide)
tsDMARD - targeted (like apremilast or tofacitinib)
boDMARD - biologic originator (like Remicade)
bsDMARD - biosimilar (like Inflektra)
If you want to know more about acronyms and studies, here's the link to
the book: http://www.weltbild.de/3/16398619-1/buch/clinical-trials-in-rheumatology.html
I've checked some of the studies with this book.
Updated:
28.02.2018 /
